Decreased plasma nesfatin-1 levels in patients with acute myocardial infarction

Dai, Hongji; Li, Xiaolu; He, Tao; Wang, Yanping; Wang, Zhengzhong; Wang, Shoudong; Xing, Mingqing; Sun, Wenjuan; Ding, Huanzhong

doi:10.1016/j.peptides.2013.06.006

Cited by 45 publications

(45 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Numerous neuropeptides have been discussed due to their tumor-promoting effects (18). NUCB2 was suggested to promote the proliferation of various cells, including adipocytes and pancreatic cells (12,22,23). In addition, it has been suggested that NUCB2 is highly expressed in the cancer of breast, stomach, ovarian epithelium, prostate and kidneys, according to serological identification and expression analysis (6,(13)(14)(15)(16)24).…”

Section: Discussionmentioning

confidence: 99%

A novel function of NUCB2 in promoting the development and invasion of renal cell carcinoma

et al. 2017

Oncol Lett

View full text Add to dashboard Cite

Abstract. Previous studies have assessed nucleobindin 2 (NUCB2) expression in multiple urological cancer cell lines and detected its effect on renal cancer cell apoptosis. Additionally, certain reports have indicated a novel function of NUCB2 in promoting invasion in renal cancer. The levels of NUCB2 expression in different tumor cell lines were detected by quantitative reverse transcription polymerase chain reaction (RT-qPCR). Human NUCB2 and β-actin (ACTB) cDNA plasmids were inserted into lentivirus plasmids, which were then transfected into 786-O cells. Western blotting and RT-qPCR were then performed to determine the gene expression in NUCB2-knocked down cells. Apoptosis was also examined by flow cytometry subsequent to successful transfection. Finally, a transwell invasion assay was performed to investigate the effects on invasive abilities in renal cancer cells. The RT-qPCR results demonstrated a high expression of NUCB2 in 786-O, ACHN and LNCaP cells, and there was particularly high expression in renal cancer 786-O cells. Following successful transfection, downregulation of NUCB2 facilitated renal carcinoma cell apoptosis, as demonstrated by an increased apoptosis rate in the lenti-NUCB2-KD 786-O cells (13.72±0.84 vs. 3.32±0.10; lenti-NUCB2-KD group vs. negative control). Notably, a significant decreased invasion rate was observed in the NUCB2 knocked-down cells compared with negative control, suggesting an invasion-promoting effect of NUCB2. These results suggested a novel function of NUCB2 in the process of development and invasion in renal cell carcinoma. NUCB2 may be an important prognostic factor and target in the diagnosis and treatment of human renal cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

A novel function of NUCB2 in promoting the development and invasion of renal cell carcinoma

et al. 2017

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…Dai et al [9] have shown that serum nesfatin-1 levels were lower in individuals with acute myocardial infarction (AMI) compared to the angina pectoris group and the control group, in a study involving 156 individuals. In addition, plasma nesfatin-1 levels were inversely correlated with high sensitivity C reactive protein (hs-CRP), neutrophil percentage, and Gensini score in the AMI group.…”

Section: Introductionmentioning

confidence: 99%

Nesfatin-1 levels in patients with slow coronary flow

Kuyumcu

Yayla

et al. 2018

Kardiol Pol

View full text Add to dashboard Cite

show abstract

“…3 Interestingly, fasting plasma levels of nesfatin-1 were significantly lower in patients with acute myocardial infarction. 4 Nesfatin-1 is a newly discovered anorexigenic hormone, and whether it is involved in the development of clinical obesity is not clear. The nesfatin-1/ NUCB2 ratio in cerebrospinal fluid /plasma is negatively associated with body mass index (BMI), body weight, fat mass and cerebrospinal fluid glucose level.…”

Section: Introductionmentioning

confidence: 99%

Plasma Nesfatin-1 Level in Obese Patients after Acupuncture: A Randomised Controlled Trial

et al. 2014

Self Cite

View full text Add to dashboard Cite

Background Nesfatin-1 is an anorexigenic hormone suggested to regulate obesity. Objective To investigate the relationship between nesfatin-1 level and anthropometric and metabolic parameters in obese patients, and examine the change in plasma nesfatin-1 level after acupuncture treatment. Methods 64 obese adult patients without diabetes and 58 normal weight control subjects were enrolled in this study. The obese patients were randomly divided into an acupuncture plus diet group (n=32) and a diet only group (n=32). Measurements were repeated after 45 days. Results Body mass index (BMI), waist and hip circumferences, serum insulin, lipoprotein and insulin resistance measures were significantly higher, and plasma nesfatin-1 level was significantly lower, in obese patients than in normal weight controls. In addition, negative correlations were found between plasma nesfatin-1 level and BMI, waist and hip circumferences. Weight reduction in participants after acupuncture and diet restriction was 7.0% and 4.3%, respectively. Plasma nesfatin-1 level increased from 2.75±1.16 to 3.44±1.28 ng/mL and from 2.86±1.07 to 3.23±1.06 ng/mL in acupuncture and diet groups, respectively; the difference was significant, p<0.05. Conclusions Plasma nesfatin-1 level is reduced in obese adults, and is increased after acupuncture. The beneficial effect of acupuncture on obesity is associated with increased plasma nesfatin-1 level.

show abstract

Decreased plasma nesfatin-1 levels in patients with acute myocardial infarction

Cited by 45 publications

References 29 publications

A novel function of NUCB2 in promoting the development and invasion of renal cell carcinoma

A novel function of NUCB2 in promoting the development and invasion of renal cell carcinoma

Nesfatin-1 levels in patients with slow coronary flow

Plasma Nesfatin-1 Level in Obese Patients after Acupuncture: A Randomised Controlled Trial

Contact Info

Product

Resources

About